Insulin is a growth stimulating hormone for several malignant tumors. In experimental breast cancer, diabetes induction with alloxan, strep-tozotocin or diazoxide leads to remission and intensifies the effect of an ovariectomy and of antiestrogen treatment. Clinically, in one of nine breast cancer patients, a partial remission of dermal metastases of seven months duration was achieved following a tamoxifen-induced remission by additional treatment with 200 mg diazoxide daily. In two other breast cancer patients, diazoxide led to stable disease of four (monotherapy) and eight months duration. Increased insulin levels can enhance the effect of simultaneous cytostatic therapy in a number of experimental systems. Initial clinical trials of combined therapy with methotrexate (MTX)/5-fluorouracil (5FU) and glucose/insulin indicate an increased cytostatic effect of this combination in some patients with breast cancer and in two patients with colon cancer, who were both pretreated with the same MTX/5FU regimen without glucose/insulin. In a case treated with high dose methotrexate therapy, the decrease of serum MTX-levels was slightly accelerated during and markedly delayed after the end of the glucose/ insulin-infusion.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.